English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Transforming growth factor β-1 (TGF-β1) is an immunosuppressive cytokine. It exerts cardioprotection during acute myocardial ischaemia, promoting healing of the injured myocytes. Lower plasma concentrations of TGF-β1 have been identified in patients with coronary artery disease (CAD) compared to those with normal coronary arteries. We measured plasma TGF-β1 concentrations in patients with CAD compared to those with degenerative heart valves (DHVs) and normal coronary arteries. The mean concentration of TGF-β1 in patients with valvular heart disease was significantly lower (18.67 μg/l) than the mean in the coronary artery bypass graft (CABG) group (26.46 μg/l). There was no correlation between the patient characteristics and preoperative concentration of TGF-β1. It is possible that the lower plasma concentration of TGF-β1 in patients with valvular heart disease and the lack of its regulatory effect results in the increased inflammation and calcification seen in DHVs.

Identification of low circulatory transforming growth factor β-1 in patients with degenerative heart valve disease☆